Independent Research set a €102.00 ($118.60) price target on Merck KGaA (FRA:MRK) in a research report report published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other equities research analysts also recently weighed in on the company. Deutsche Bank set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a report on Thursday, May 16th. DZ Bank reissued a buy rating on shares of Merck KGaA in a report on Tuesday, July 23rd. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the stock a neutral rating in a report on Tuesday, June 18th. UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the stock a neutral rating in a report on Thursday, August 8th. Finally, Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the stock a buy rating in a report on Monday, June 17th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of €100.67 ($117.05).
MRK opened at €94.50 ($109.88) on Friday. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72). The stock’s fifty day moving average price is €93.64.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.